- Novel Sulfonaminoquinoline Hepcidin Antagonists
-
The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
- -
-
Page/Page column 141
(2012/09/05)
-
- COMPOUNDS THAT INHIBIT NFκB ACTIVITY
-
The present invention relates to compounds with activity as BACE1 and NFκB modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment o
- -
-
Page/Page column 7; 38
(2010/05/14)
-
- Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation
-
We describe here a series of N-(quinolin-8-yl)benzenesulfonamides capable of suppressing the NFκB pathway identified from two high-throughput screens run at two centers of the NIH Molecular Libraries Initiative. These small molecules were confirmed in bot
- Xie, Yuli,Deng, ShiXian,Thomas, Craig J.,Liu, Yidong,Zhang, Ya-Qin,Rinderspacher, Alison,Huang, Wenwei,Gong, Gangli,Wyler, Michael,Cayanis, Efithia,Aulner, Nathalie,Toebben, Udo,Chung, Caty,Pampou, Sergey,Southall, Noel,Vidovic, Dusica,Schuerer, Stephan,Branden, Lars,Davis, R. Eric,Staudt, Louis M.,Inglese, James,Austin, Christopher P.,Landry, Donald W.,Smith, Deborah H.,Auld, Douglas S.
-
p. 329 - 335
(2008/09/16)
-